Hitting the Target: Developing High-quality Evidence for Proton Beam Therapy Through Randomised Controlled Trials

Eleanor Hudson(University of Leeds), Emma Hall(Institute of Cancer Research), David Sebag‐Montefiore(University of Leeds), Katie Biscombe(Institute of Cancer Research), Anna M. Kirby(Royal Marsden NHS Foundation Trust), Sarah Brown(University of Leeds), Finbar Slevin(University of Leeds), David Thomson(The Christie NHS Foundation Trust), Louise Murray(Leeds Teaching Hospitals NHS Trust), Joanne Haviland(Institute of Cancer Research)
Clinical Oncology
November 8, 2023
10.1016/j.clon.2023.11.027
Cited by 8

Related Papers

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
|The Lancet|2009|1.5k
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials
|The Lancet Oncology|2013|1.4k
Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial
|The Lancet|2009|1.1k